These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 3726073)
21. [Postmarketing surveillance of adverse reactions of drugs]. Polli EE; Cortellaro M Ann Ital Med Int; 1989; 4(1):1-9. PubMed ID: 2702012 [No Abstract] [Full Text] [Related]
22. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid]. Lagier G; Vincens M; Castot A Therapie; 1983; 38(3):303-18. PubMed ID: 6612667 [No Abstract] [Full Text] [Related]
23. [Comparative organization of drug monitoring in France and 7 European countries]. Vaissere J; de Cremiers F; Auriche M; Juillet Y Therapie; 1986; 41(5):369-74. PubMed ID: 3810527 [No Abstract] [Full Text] [Related]
24. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period]. Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M Therapie; 1986; 41(5):375-7. PubMed ID: 3810528 [No Abstract] [Full Text] [Related]
29. Use of an algorithm to evaluate published reports of adverse drug reactions. Case B; Oszko MA Am J Hosp Pharm; 1991 Jan; 48(1):121-2. PubMed ID: 2000870 [No Abstract] [Full Text] [Related]
30. [How to assess the risk of drugs?]. Roujeau JC Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953 [No Abstract] [Full Text] [Related]
31. How should we react to adverse drug reactions? Ferner RE; Beard K Postgrad Med J; 2011 Feb; 87(1024):81-2. PubMed ID: 21303818 [No Abstract] [Full Text] [Related]
32. [Microcomputerized data bank of nephrotoxic drugs at the Paris-Saint Antoine Regional Drug Monitoring Center]. Hamel JD; Biour M; Cheymol G Therapie; 1986; 41(5):327-9. PubMed ID: 3810519 [No Abstract] [Full Text] [Related]
33. Adverse drug reactions: a review of relevant factors. Ajayi FO; Sun H; Perry J J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248 [TBL] [Abstract][Full Text] [Related]
34. Food and Drug Administration monitoring of adverse drug reactions. Sills JM; Tanner LA; Milstien JB Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612 [TBL] [Abstract][Full Text] [Related]
35. [Information centers on undesirable effects of drugs: also on alerting function]. Bégaud B; Péré JC; Tubert P; Barat C; Haramburu F; Albin H Therapie; 1987; 42(2):231-7. PubMed ID: 3617000 [No Abstract] [Full Text] [Related]
36. International monitoring for adverse drug reactions of long latency. Fletcher AP; Griffin JP Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771 [No Abstract] [Full Text] [Related]
37. Review of Canadian pharmacist involvement in adverse drug reaction reporting. Taras-Zasowski KM; Einarson TR Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271 [TBL] [Abstract][Full Text] [Related]
39. [Minimal information that should be found in reports about suspected adverse reactions of drugs]. Laporte JR; Lience E Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784 [No Abstract] [Full Text] [Related]
40. An underrecognized challenge in evaluating postmarketing drug safety. Roden DM Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]